Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5698730 | Clinical Oncology | 2014 | 9 Pages |
Abstract
4DCT can theoretically improve therapeutic ratio and dose escalation based on dosimetric parameters and mathematical modelling. However, when individual characteristics are incorporated, this gain may be less evident in terms of survival and dyspnoea rates. 4DCT allows potential for isotoxic dose escalation, which may lead to improved local control and better overall survival.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
A.J. Cole, J.M. O'Hare, S.J. McMahon, C.K. McGarry, K.T. Butterworth, J. McAleese, S. Jain, A.R. Hounsell, K.M. Prise, G.G. Hanna, J.M. O'Sullivan,